A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

Clinical trial NCT02584920 · COMPLETED

Trial details

NCT number: NCT02584920
Sponsor: Shanghai Henlius Biotech
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Non Hodgkin's Lymphoma

Start date: 2014-10-01
Primary completion: 2015-08-01
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.